image
Healthcare - Drug Manufacturers - General - NYSE - GB
$ 33.35
-1.91 %
$ 68 B
Market Cap
21.66
P/E
1. INTRINSIC VALUE

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews.[ Read More ]

The intrinsic value of one GSK stock under the base case scenario is HIDDEN Compared to the current market price of 33.4 USD, GSK plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GSK

image
FINANCIALS
30.3 B REVENUE
3.42%
6.74 B OPERATING INCOME
4.85%
4.93 B NET INCOME
0.14%
6.35 B OPERATING CASH FLOW
-14.25%
-1.6 B INVESTING CASH FLOW
81.82%
-5.64 B FINANCING CASH FLOW
-685.42%
8.01 B REVENUE
1.62%
189 M OPERATING INCOME
-88.52%
65 M NET INCOME
-94.46%
2.15 B OPERATING CASH FLOW
144.22%
-731 M INVESTING CASH FLOW
-100.00%
-1.24 B FINANCING CASH FLOW
5.63%
Balance Sheet Decomposition GSK plc
image
Current Assets 18.6 B
Cash & Short-Term Investments 5.69 B
Receivables 5.9 B
Other Current Assets 7.05 B
Non-Current Assets 40.4 B
Long-Term Investments 1.22 B
PP&E 9.96 B
Other Non-Current Assets 29.2 B
Current Liabilities 21.1 B
Accounts Payable 3.72 B
Short-Term Debt 2.81 B
Other Current Liabilities 14.5 B
Non-Current Liabilities 25.1 B
Long-Term Debt 15.2 B
Other Non-Current Liabilities 9.94 B
EFFICIENCY
Earnings Waterfall GSK plc
image
Revenue 30.3 B
Cost Of Revenue 9.08 B
Gross Profit 21.3 B
Operating Expenses 15 B
Operating Income 6.74 B
Other Expenses 1.82 B
Net Income 4.93 B
RATIOS
70.07% GROSS MARGIN
70.07%
22.24% OPERATING MARGIN
22.24%
16.25% NET MARGIN
16.25%
36.92% ROE
36.92%
8.35% ROA
8.35%
19.58% ROIC
19.58%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis GSK plc
image
Net Income 4.93 B
Depreciation & Amortization 2.29 B
Capital Expenditures -2.34 B
Stock-Based Compensation 307 M
Change in Working Capital -364 M
Others 1.19 B
Free Cash Flow 4 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets GSK plc
image
Wall Street analysts predict an average 1-year price target for GSK of $58 , with forecasts ranging from a low of $36 to a high of $85 .
GSK Lowest Price Target Wall Street Target
36 USD 7.95%
GSK Average Price Target Wall Street Target
58 USD 73.91%
GSK Highest Price Target Wall Street Target
85 USD 154.87%
4. DIVIDEND ANALYSIS
0.98% DIVIDEND YIELD
0.382 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership GSK plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr. Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services. forbes.com - 1 day ago
GSK plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript) GSK plc (NYSE:GSK ) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Emma Walmsley - Chief Executive Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez I'm absolutely thrilled that this we're clearly going to have the best conversation in the fireside chat that we've had so far. Incredibly pleased to have Emma Walmsley here. seekingalpha.com - 1 day ago
European And US Vaccine Stocks Are Under Pressure - Here's WHy Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services. benzinga.com - 1 day ago
GSK at two-year low, drug firms hit on vaccine sceptic US health appointment GSK PLC (LSE:GSK, NYSE:GSK) shares fell to a two-year low as AstraZeneca PLC also came under pressure on Friday after Robert F Kennedy Junior was announced as US health secretary. President-elect Donald Trump said Thursday that Kennedy, who has previously voiced anti-vax opinions, would be appointed. proactiveinvestors.co.uk - 2 days ago
GSK going nowhere while key vaccines struggle, says US bank GSK PLC (LSE:GSK, NYSE:GSK) looks undervalued, but the problem is that there is nothing on the horizon to change that perception according to analysts at US bank Jefferies. Downgrading its investment rating to 'hold', Jefferies said that the spate of good news -  favourable Zantac settlement, robust performance of Specialty, and pipeline successes – has been swamped by concerns about vaccines Shingrix (Shingles) and Arexvy (RSV). proactiveinvestors.co.uk - 5 days ago
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025 New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccines Positive Phase 2 data from seasonal influenza program licensed to GSK demonstrated strong immune responses against challenging influenza B as well as A strains; program progressing to Phase 3, which will be associated with significant milestone payment Corporate redesign on track with 30% workforce reduction, expected to yield significant annual cost savings from 2025 onwards and increase operational agility Appointment of seasoned industry executive Axel Malkomes as new CFO effective November 11, enhancing financial leadership and strategic execution CureVac to host conference call and webcast today at 9 a.m. EST / 3 p.m. accesswire.com - 5 days ago
GSK price target lowered to 1,450 GBp from 1,550 GBp at Barclays Barclays lowered the firm's price target on GSK to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares. https://thefly.com - 1 week ago
Canada approves GSK's RSV vaccine for adults aged 50 to 59 GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age group. reuters.com - 1 week ago
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand. zacks.com - 2 weeks ago
GSK plc (GSK) Q3 2024 Earnings Call Transcript GSK plc (NYSE:GSK ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcare Julie Brown - CFO Jeff McLaughlin - IR Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JPMorgan Kerry Holford - Berenberg Jo Walton - UBS Simon Baker - Redburn Atlantic Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Richard Parkes - BNP Paribas Peter Welford - Jefferies Operator Hello, everyone. Welcome to today's call and webcast. seekingalpha.com - 2 weeks ago
GSK (GSK) Q3 Earnings Surpass Estimates GSK (GSK) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago. zacks.com - 2 weeks ago
GSK: Earnings Confirm It's On Track To Meet Guidance GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. For 9m 2024, the company's turnover growth at 9% is at the upper end of the guidance range and core EPS growth of 14% exceeds it. While the numbers slumped in Q3 2024, this was expected, especially as reported earnings absorbed Zantac related payouts. They are unlikely to impact full year figures, however. seekingalpha.com - 2 weeks ago
8. Profile Summary

GSK plc GSK

image
COUNTRY GB
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 68 B
Dividend Yield 0.98%
Description GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Contact 980 Great West Road, Brentford, TW8 9GS https://www.gsk.com
IPO Date March 28, 1980
Employees 70212
Officers Mr. Tony Wood Chief Scientific Officer and Head of R&D Ms. Diana Conrad Chief People Officer Mr. Luke V. Miels Chief Commercial Officer Ms. Sally Jackson Senior Vice President of Global Communications & Chief Executive Officer Office Ms. Emma Natasha Walmsley Chief Executive Officer & Director Ms. Shobie Ramakrishnan Chief Digital & Technology Officer Mr. Philip C. Thomson President of Global Affairs Mr. James Ford Senior Vice President & Group General Counsel of Legal & Compliance Ms. Sarah Elton-Farr Head of Investor Relations Mr. David Simon Redfern BSc (Hons), CA President of Corporate Development